AU2023338199A1 - Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide - Google Patents

Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide Download PDF

Info

Publication number
AU2023338199A1
AU2023338199A1 AU2023338199A AU2023338199A AU2023338199A1 AU 2023338199 A1 AU2023338199 A1 AU 2023338199A1 AU 2023338199 A AU2023338199 A AU 2023338199A AU 2023338199 A AU2023338199 A AU 2023338199A AU 2023338199 A1 AU2023338199 A1 AU 2023338199A1
Authority
AU
Australia
Prior art keywords
cancer
cocrystalline
urothelial
cocrystalline form
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023338199A
Other languages
English (en)
Inventor
David Andrew Coates
Lori Raquel HILDEN
Gislaine KUMINEK
Jeffrey A. Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2023338199A1 publication Critical patent/AU2023338199A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023338199A 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide Pending AU2023338199A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
AU2023338199A1 true AU2023338199A1 (en) 2025-03-20

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023338199A Pending AU2023338199A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Country Status (18)

Country Link
US (1) US20240116932A1 (https=)
EP (1) EP4584270A1 (https=)
JP (2) JP7541606B2 (https=)
KR (1) KR20250057022A (https=)
CN (1) CN120187720A (https=)
AR (1) AR130417A1 (https=)
AU (1) AU2023338199A1 (https=)
CA (1) CA3266872A1 (https=)
CL (1) CL2025000596A1 (https=)
CO (1) CO2025002467A2 (https=)
CR (1) CR20250077A (https=)
DO (1) DOP2025000054A (https=)
IL (1) IL319342A (https=)
JO (1) JOP20250053A1 (https=)
MX (1) MX2025002687A (https=)
PE (1) PE20251400A1 (https=)
TW (1) TWI862146B (https=)
WO (1) WO2024054814A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962600B1 (en) * 2005-12-08 2013-05-01 New Form Pharmaceuticals Inc. Metronidazole cocrystals
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
WO2024054814A1 (en) 2024-03-14
JP2024037713A (ja) 2024-03-19
CO2025002467A2 (es) 2025-03-17
CN120187720A (zh) 2025-06-20
CR20250077A (es) 2025-04-02
CA3266872A1 (en) 2024-03-14
JOP20250053A1 (ar) 2025-03-06
EP4584270A1 (en) 2025-07-16
JP7541606B2 (ja) 2024-08-28
US20240116932A1 (en) 2024-04-11
DOP2025000054A (es) 2025-03-31
CL2025000596A1 (es) 2025-04-25
PE20251400A1 (es) 2025-05-22
JP2024153948A (ja) 2024-10-29
KR20250057022A (ko) 2025-04-28
IL319342A (en) 2025-05-01
AR130417A1 (es) 2024-12-04
TWI862146B (zh) 2024-11-11
MX2025002687A (es) 2025-04-02
TW202428260A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
CN111362967B (zh) 苯并氧杂二氮杂十四碳烯衍生物及其用途
KR102359993B1 (ko) 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
JP2019524883A (ja) Ｆｇｆｒ阻害剤としての複素環化合物
CN118791505A (zh) 一种含肟结构的杂环化合物及其制备方法与用途
JP2024153948A (ja) Ｆｇｆｒ３阻害剤の共結晶形態
CN107382840B (zh) 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN112110938A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
CN105218548A (zh) 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
WO2018157737A1 (zh) 一种多靶点激酶抑制剂
TW202421139A (zh) 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法
CN110256405A (zh) 5-烃基-n-取代芳基吡啶酮衍生物及其制备方法和用途
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
JP2005524671A (ja) 新規アゼパン誘導体類
CN111892536B (zh) 取代的喹啉甲酰胺类化合物及其用途
CN111362871B (zh) 取代的吡啶-2-甲酰胺类化合物及其用途
CN111247143B (zh) 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物
CN113493437B (zh) 含苯并咪唑结构的化合物及其制备方法和用途
TW202604502A (zh) Ｓｈｐ２抑制劑的新的晶型及其用途
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
WO2025026368A1 (zh) R406及其衍生物协同trail的抗肿瘤应用
JP2025536818A (ja) 縮合環式化合物の固体形態、及びその製造方法並びに使用